Recombinant Hyaluronidase
(Hybrozyme™)
|
ALT-B4
(SC Enabling)
|
MSD's Keytruda Qlex received FDA approval and launched/marketed in the U.S.
|
Licensed to six companies, including MSD, which launched Keytruda Qlex, the subcutaneous version of Keytruda (pembrolizumab and berahyaluronidase alfa-pmph)
|
ALT-BB4
(Stand-alone)
|
MFDS Approved, Commercialization in Korea
|
Tergase® Commercialization in Korea
Indication Expansion and Global L/O in Progress
|
|
Biosimilars *
|
ALT-L9
(wetAMD)
|
Received EMA approval, currently under MFDS review
|
Partnered with Alteogen Biologics, a subsidiary of Alteogen
|
ALT-L2
(Breast & Gastric Cancer)
|
NMPA Approved, Commercialization in China
|
Commercialization in China
|
Long-acting Biobetter
(NexP™)
|
ALT-P1
(Human Growth Hormone)
|
Phase 2 Completed for Adult Indication
|
|
Phase 2 in Pediatric Growth Hormone Deficiency
|
|
ALT-B5
(Acromegaly)
|
|
Selected for National New Drug Development Task in 2021
|
ADC
(NexMab™)
|
ALT-P7
(Breast & Gastric Cancers)
|
|
|
